TBX21

Across TCGA pan-cancer cohorts, TBX21 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TBX21 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TBX21 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TBX21 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, LGG, and HNSC are the cancer types where TBX21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.171	0.542	.008	24	view →
LGG	DFS	Median	All	0.083	0.833	<.001	12	view →
HNSC	DFS	Median	III,IV	0.128	0.680	.005	12	view →
UCEC	DFS	Median	All	1.000	0.632	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TBX21–OV (DFS)

Open the OV breakdown →